DaVita (NYSE:DVA) Issues Earnings Results

DaVita (NYSE:DVA) posted its earnings results on Thursday. The company reported $3.82 earnings per share for the quarter, topping the consensus estimate of $3.57 by $0.25, FiscalAI reports. DaVita had a net margin of 6.49% and a negative return on equity of 215.05%. The firm had revenue of $3.58 billion during the quarter, compared to the consensus estimate of $3.52 billion. During the same quarter last year, the company earned $2.51 earnings per share. The company’s revenue was up 4.6% on a year-over-year basis.

Here are the key takeaways from DaVita’s conference call:

• Integrated Kidney Care (IKC) is outperforming expectations, with 2026 adjusted operating income now expected to be at least $65 million—$25 million above prior guidance and $45 million above 2025. DaVita cited improving savings rates, lower hospital utilization and the new Humana partnership as growth drivers.
• DaVita will begin the national rollout of its expanded HD dialyzer next week, following pilots across 150 centers involving more than 10,000 patients. More than 90% of eligible pilot patients adopted the technology, though meaningful mortality and volume benefits are not expected until the second half of 2028.
• Third-quarter treatment volume increased 1.2% year over year, supported by a roughly 1% rise in patient census as mortality improves. The company expects 2027 volume growth to exceed 2026 levels, although Q4 faces an approximately 1% unfavorable day-mix effect.
• DaVita narrowed its 2026 outlook to adjusted operating income of $2.175 billion-$2.25 billion and adjusted EPS of $14.30-$15.20, reflecting higher-than-planned U.S. dialysis costs—particularly technology spending that grew more than 20% year over year. Commercial mix pressure from expiring ACA enhanced premium tax credits is expected to create a roughly $40 million headwind.
• The finalized 2027 ESRD rule is estimated to provide a 1.5%-2% full-year net rate benefit, but the reported 3.5% Q1 increase for large dialysis organizations will decline materially after the first quarter as TDAPA payments are recalculated quarterly. DaVita said the impact is driven mainly by DefenCath rather than phosphate binders.

DaVita Price Performance

NYSE:DVA traded down $6.13 during trading hours on Friday, hitting $187.18. The stock had a trading volume of 1,760,632 shares, compared to its average volume of 709,209. The company has a 50 day simple moving average of $181.36 and a two-hundred day simple moving average of $176.50. DaVita has a one year low of $101.00 and a one year high of $247.49. The firm has a market capitalization of $11.94 billion, a price-to-earnings ratio of 13.78, a P/E/G ratio of 0.50 and a beta of 0.80.

Analyst Upgrades and Downgrades

Several research firms recently commented on DVA. Oppenheimer set a $220.00 price objective on shares of DaVita in a report on Friday, August 7th. Weiss Ratings raised shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, October 9th. Truist Financial dropped their target price on DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a research report on Friday, August 7th. Wall Street Zen lowered DaVita from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Barclays increased their price objective on DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $233.43.

Key DaVita News

Here are the key news stories impacting DaVita this week:

• Positive Sentiment: Strong quarterly beat: DaVita reported adjusted earnings of $3.82 per share, above the $3.57 FactSet consensus, while revenue rose 4.6% year over year to $3.58 billion, exceeding the $3.52 billion estimate. DaVita Q3 adjusted EPS earnings flash
• Positive Sentiment: Kidney Care and international growth supported results: Earnings increased sharply from the prior-year period, with reported net income attributable to common shareholders rising 48.3% to $222.9 million. The company’s integrated kidney care operations were highlighted as a key growth driver. DaVita Q3 earnings beat and growth
• Neutral Sentiment: Profitability was mixed: Operating profit declined 1.3% year over year to $499.3 million, suggesting that higher costs and margin pressure offset some of the revenue growth. Cash flow from operations also fell to $518.8 million, while capital spending totaled $159.5 million. DaVita Q3 2026 financial results
• Negative Sentiment: $62 million China charge weighed on sentiment: Reports indicate a charge related to China reduced the quality of the quarter’s headline beat and raised concerns about potential additional costs or operational issues. DaVita China charge and Q3 earnings
• Negative Sentiment: Additional overhangs include insider selling and a legal investigation: Recent data shows several insiders, including Berkshire Hathaway and DaVita executives, selling shares, while Pomerantz LLP announced an investigation on behalf of investors. Neither necessarily indicates wrongdoing, but both developments may add near-term uncertainty. Pomerantz DaVita investor investigation

About DaVita

DaVita Inc (NYSE: DVA) is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.